Clinical Trials Browser

NCT04145375 2026-05-08

Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

Phase 1/2 Enrolling by invitation

40 enrolled

Genitourinary

Prostatic Neoplasms

NCT00900497 2026-05-01

A Study Using White Blood Cells From Healthy Donors To Treat Solid Cancers

Phase 1/2 Enrolling by invitation

29 enrolled

Graft vs Host Disease

NCT03393962 2026-04-24

Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors

Phase 1/2 Enrolling by invitation

20 enrolled

Gynecologic

Ovarian Neoplasms

NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Phase 1/2 Enrolling by invitation

30 enrolled

CNS

Adenoviridae Infections, Glioma

NCT07126990 2026-03-23

Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma

Phase 1/2 Enrolling by invitation

40 enrolled

CNS

Glioma

NCT05741242 2026-01-15

A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors

Phase 1/2 Enrolling by invitation

136 enrolled

Tumor-Agnostic

Neoplasms

NCT05570994 2026-01-08

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Phase 1/2 Enrolling by invitation

50 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Phase 1/2 Enrolling by invitation

30 enrolled

BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT07210047 2025-10-07

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Phase 1/2 Enrolling by invitation

21 enrolled

Plasma cell

Multiple Myeloma

NCT05893654 2025-09-15

MELCOM

Phase 1/2 Enrolling by invitation

10 enrolled

Dermatologic

Uveal Melanoma, Melanoma

NCT06936527 2025-09-03

XS-03-II201

Phase 1/2 Enrolling by invitation

102 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Phase 1/2 Enrolling by invitation

52 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT06027879 2025-06-25

Gamma Capture

Phase 1/2 Enrolling by invitation

25 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

NCT06992687 2025-05-28

A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors

Phase 1/2 Enrolling by invitation

30 enrolled

Other solid neoplasm

Solid Tumors

NCT06768268 2025-04-16

ICGMV

Phase 1/2 Enrolling by invitation

30 enrolled

Breast

Breast Neoplasms

NCT06690216 2025-03-30

PD-L1-PET

Phase 1/2 Enrolling by invitation

100 enrolled

CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma

NCT06890871 2025-03-24

Radiotherapy with Immunotherapy and Anti-Angiogenic Therapy for Advanced HER2-Negative Breast Cancer: a Single-Arm Study

Phase 1/2 Enrolling by invitation

25 enrolled

Breast

Breast Neoplasms

NCT01868490 2025-02-10

The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells

Phase 1/2 Enrolling by invitation

20 enrolled

CNSGastrointestinal

Neuroblastoma, Cholangiocarcinoma

NCT06762431 2025-01-07

VTB-CLL002

Phase 1/2 Enrolling by invitation

60 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06303583 2024-03-12

CRIS

Phase 1/2 Enrolling by invitation

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma